Insider Selling: Scholar Rock (NASDAQ:SRRK) Director Sells $137,045.28 in Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Michael Gilman sold 2,544 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $53.87, for a total transaction of $137,045.28. Following the completion of the transaction, the director owned 59,511 shares of the company’s stock, valued at approximately $3,205,857.57. This trade represents a 4.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Stock Down 0.9%

NASDAQ:SRRK opened at $56.03 on Thursday. Scholar Rock Holding Corporation has a one year low of $27.07 and a one year high of $57.80. The company has a debt-to-equity ratio of 0.71, a current ratio of 8.64 and a quick ratio of 8.64. The company has a market cap of $6.71 billion, a PE ratio of -15.61 and a beta of 0.67. The firm’s 50 day simple moving average is $48.99 and its 200 day simple moving average is $46.85.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same quarter in the previous year, the company earned ($0.67) EPS. On average, research analysts anticipate that Scholar Rock Holding Corporation will post -3.23 earnings per share for the current year.

Institutional Trading of Scholar Rock

A number of institutional investors have recently bought and sold shares of the company. Siren L.L.C. raised its position in shares of Scholar Rock by 17.0% in the 4th quarter. Siren L.L.C. now owns 10,825,013 shares of the company’s stock worth $476,842,000 after acquiring an additional 1,575,008 shares in the last quarter. Redmile Group LLC boosted its position in shares of Scholar Rock by 73.7% during the 1st quarter. Redmile Group LLC now owns 9,066,621 shares of the company’s stock valued at $445,715,000 after purchasing an additional 3,845,775 shares in the last quarter. Wellington Management Group LLP grew its stake in Scholar Rock by 26.7% during the fourth quarter. Wellington Management Group LLP now owns 5,759,428 shares of the company’s stock worth $253,703,000 after purchasing an additional 1,213,541 shares during the period. Vanguard Group Inc. increased its holdings in Scholar Rock by 5.7% in the fourth quarter. Vanguard Group Inc. now owns 5,195,465 shares of the company’s stock worth $228,860,000 after purchasing an additional 280,538 shares in the last quarter. Finally, State Street Corp increased its holdings in Scholar Rock by 7.2% in the fourth quarter. State Street Corp now owns 4,034,434 shares of the company’s stock worth $177,717,000 after purchasing an additional 271,331 shares in the last quarter. Institutional investors own 91.08% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the company. JPMorgan Chase & Co. lifted their target price on Scholar Rock from $47.00 to $50.00 and gave the stock an “overweight” rating in a report on Monday, March 16th. Wedbush raised their price objective on Scholar Rock from $56.00 to $58.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research note on Tuesday, April 21st. Barclays upped their target price on Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Finally, Canaccord Genuity Group assumed coverage on shares of Scholar Rock in a research report on Monday, April 20th. They set a “buy” rating and a $62.00 target price for the company. Four analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $56.00.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).